Mission MalariaMission Malaria

Partnering Healthcare GloballyPartnering Healthcare GloballyIpca Laboratories Limited

Nov 2008Nov 2008

Ipca

Ipca OverviewIpca Overview

Incorporation 1949

Present Management since 1975

Total Income F.Y. 2007-08 USD 271 Mn.

Exports F.Y. 2007-08 (Over 110 Countries)

USD 134 Mn.

Number of Employees Over 6,000

Business Model

Fully integrated Pharmaceutical

company producing Branded & Generics Formulations, APIs &

Intermediates.

Revenue Break-up (2007-08)

Formulations 74%

APIs 26% Domestic 49%Exports 51%

Europe

Africa

Asia

CIS

America

Australasia

Tot

al R

even

ue B

reak

up

Tot

al R

even

ue B

reak

up

.

-47%

-15%

-14%

-11%

Con

tinen

t wis

e Sa

les

- 11%

Ipca HighlightsIpca Highlights

Among top 10 Pharma Exporters from India.

6 Formulation and 3 API plants.

Among “Top 200 Best Under a Billion Companies outside USA”

(Forbes Asia) in 2003, 2004, 2005, & 2007

Life Time Achievement Award from Chemexcil.

National Energy Conservation Award in 2007

D&B-ECGC Indian Exporters Excellence Award-2008.

Separate API R&D Team ( 200 Scientists) & Formulation Team (120

Scientists).

Strong Regulatory Team - Dossiers approved in U.S.A, EU, Australia.

6 Formulation Facilities

WHO, Geneva

USFDA *MHRA UKTGA AustraliaMCC South AfricaHPB- Canada

Major Major Approvals Approvals

Athal (Silvassa)Athal (Silvassa)

* * USFDA is for Piparia Plant (SilvassaUSFDA is for Piparia Plant (Silvassa))

Capacity 8 Bln TabletsCapacity 8 Bln Tablets

3 API FacilitiesWe make around 100 APIs with over 40 DMFs filed with US FDA.

MajorMajorApprovalsApprovals

WHO, GenevaUSFDA EDQM-EuropeTGA AustraliaDanish Reg PMDA -Japan

RatlamRatlam

One of the largest manufacturers of APIs like Artemisinin Derivatives,Amodiaquine,Chloroquine, Atenolol, Propanolol,, Pyrantel Salts,

Furosemide, Losartan, HCQS

Ipca’s “Mission Malaria”

Helping to Save a million lives

globally

Ipca’s Vision - Malaria

Committed to the cause of helping to save a million lives

Offering wide range of Effective drugs at affordable price

Striving to improve Access for Effective Market Penetration

Forging strong links with WHO, UNICEF, Global Fund, Clinton

Foundation, MOH in Africa and other major stake holders.

To be a Globally acknowledged Anti Malarial Company.

Special dedicated team formed for Mission Malaria

Ipca’s Strengths in Malaria

India’s Market Leader with 30% market share.(3 times bigger than the nearest competitor)

Broad range of Anti Malarials API’s & Formulations

Strong backward integration by manufacturing mostAnti- Malarial API’s to back up formulations.

20% of turnover from Anti Malarials – around USD 50 mln

IpcaIpca’s Strengths in Malaria

500 hectares of crop… Tie ups in place..

Ipca’s Strengths – APIs

World’s largest manufacturer of Chloroquine Phosphate. Cumulative production in 23 years of over 7 mln tonnes.

One of the world’s largest manufacturers of Artemisininbased APIs & Formulations.

Already growing Artemisia crop in various states in India.

One of the few sources approved by WHO for Amodiaquine, Artemether, Artesunate & Lumefantrine.

13 APIs sold in 50 countries.

Ipca’s Strengths – Formulations

In April’08 Ipca became the 1st Indian company & the 2nd company in the world to have

WHO prequalification for Artesunate 50mg + Amodiaquine 153.1mg Co-blister tablets.

Strong Pipeline of drugs for WHO filing.

Global Fund Listing

A – Artesunate + Amodiaquine Co-blister Tablets

C i – Artemether + Lumefantrine Tablets

Dedicated Anti – Malarial Division in India - 500 medical reps.

Over 30 years experience in Anti Malarial formulations.

Approved suppliers to UNICEF, WHO - Geneva, MSF- France and other reputed

Institutional bodies.

Artesunate + Amodiaquine Tablets (FDC)

Artesunate + Sulphadoxine + Pyrimethamine TabletsC ii

Ipca – NCE Research in Malaria

1st IND Application approved by regulatory authorities for Phase I Human trials - In licensing arrangement with CSIR labs - NCE 97 / 78 CDRI compound – Anti Malarial Segment.

Collaboration with CDRI for developing synthetic trioxanes (CDRI 99/411)

Collaboration with IISc, Bangalore, National Institute of Malaria Research, New Delhi for combination of Artesunate + Curcumin.

Partnerships

1st Company in the world with whom the Clinton Foundation has signed a partnership agreement for supply of Artesunate 50mg + Amodiaquine 153.1mg co-blister tablets

An agreement for Artemether 20mg + Lumefantrine 120mg tablets has also being signed

Anti Malaria Production data

S.No. API Name

Year of Starting

Production

Cumulative Production from

start till Mar-08 (Qty in Kgs)

1 Artesunate 2000 28,953

2 Artesunate Sterile 2000 996

3 Arteether 2001 7,103

4 Artemether 1998 7,624

5 Artemotil 2004 327

6 Lumefantrine 2005 11,213

7 Amodiaquine Base 1988 187,129

8 Amodiaquine Hcl 1988 691,321

9 Chloroquine Phosphate 1985 6,993,782

10 Chloroquine Sulphate 1994 78,502

11 Primaquine Phosphate 2003 9,514

12 Piperaquine Phosphate 2005 2,644

TOTAL 8,019,108

Ipca’s Anti Malarial Product Range

• APIs • FormulationsBrand Name Generic Name1. Larither Artemether2. Ipcaquine Amodiaquine3. Lumerax Artemether +Lumefantrine

4. Larisunate Artesunate5. Larimal Artesunate +Amodiaquine

6. Artemef Artesunate +Mefloquine

7. Artidox Artesunate+Sulphadoxine+ Pyrimethamine

8. Larinate9. Betamotil

Artesunate SterileBeta - Arteether

10. Lariago Chloroquine phosphate11. Larimef Mefloquine12. Laridox Sulphadoxine-

Pyrimethamine13. Cinkona Quinine14. Malirid Primaquine

S.No Molecule Name1 Artesunate

2 Artesunate Sterile

3 Arteether

4 Artemether

5 Artemotil

6 Lumefantrine

7 Amodiaquine Base

8 Amodiaquine Hcl

9 Chloroquine Phosphate

10 Chloroquine Sulphate

11 Primaquine Phosphate

12 Piperaquine Phosphate

13 Proguanil HclMore API's & Formulations in pipeline

Malaria kills a child every 30 seconds.

The countdown has begun.

The time to act is Now - Together.